BGB-58067 in Newly Diagnosed Glioblastoma
About the Newly Diagnosed Glioblastoma Clinical Trial
The Ivy Brain Tumor Center at Barrow Neurological Institute, a nonprofit translational research program, is conducting a Phase 0/2 clinical trial to evaluate BGB-58067, an MTA cooperative PRMT5 inhibitor, in newly diagnosed glioblastoma (GBM) patients.
This Phase 0/2 clinical trial will evaluate the blood-brain barrier penetration of BGB-58067 in patients with newly diagnosed GBM, and measure tumor response to the drug. Patients with MTAP-deleted GBM demonstrating adequate drug penetration may be eligible for continued treatment in combination with fractionated radiotherapy in the trial’s expansion phase. Based on genetic testing results of their brain tumor, some patients will also receive the standard of care treatment temozolomide.
Glioblastoma Trial Details
Recruiting
BGB-58067
Newly Diagnosed Glioblastoma
NCT07485049
You may be eligible if:
- You are 18 years or older.
- You have been recently diagnosed with a suspected glioblastoma and have not received any tumor-directed intervention other than a biopsy.
- You have adequate bone marrow and organ function.
How it works
Once enrolled, a patient receives a short exposure to the experimental therapy days before a planned operation to remove their tumor.
The exposure to the experimental therapy is enough that when we remove the tumor, our team of experts can answer an important question: Did the treatment penetrate the tumor?
If the drug penetrates the tumor at sufficient levels, the patient may move forward with receiving the experimental treatment in combination with fractionated radiotherapy in the therapeutic expansion phase. Some patients will also receive standard of care temozolomide.
Alternatively, if the treatment has no effect on the tumor, the patient can enroll in another clinical trial without losing time or receiving ineffective treatment.
Am I Eligible?
Submit a free trial screening request today to learn if you may qualify for any of our studies.
